Weak Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis.
Adult
Antigens, CD
/ metabolism
Antigens, Differentiation, T-Lymphocyte
/ metabolism
B7-1 Antigen
/ metabolism
Biopsy
CD4 Antigens
/ metabolism
CD8 Antigens
/ metabolism
Colitis, Ulcerative
/ diagnostic imaging
Colon, Sigmoid
/ pathology
Colonoscopy
/ methods
Female
Humans
Hyperplasia
/ classification
Immunohistochemistry
/ instrumentation
Intestinal Mucosa
/ metabolism
Lectins, C-Type
/ metabolism
Lysosomal-Associated Membrane Protein 1
/ metabolism
Lysosomal-Associated Membrane Protein 2
/ metabolism
Male
Middle Aged
Proctocolectomy, Restorative
/ standards
Prospective Studies
RNA, Messenger
/ metabolism
Survival Analysis
T-Lymphocytes, Cytotoxic
/ metabolism
Journal
Clinical and translational gastroenterology
ISSN: 2155-384X
Titre abrégé: Clin Transl Gastroenterol
Pays: United States
ID NLM: 101532142
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
pubmed:
26
7
2019
medline:
1
9
2020
entrez:
26
7
2019
Statut:
ppublish
Résumé
In patients with ulcerative colitis (UC), dysplasia develops in 10%-20% of cases. The persistence of low-grade dysplasia (LGD) in UC in 2 consecutive observations is still an indication for restorative proctocolectomy. Our hypothesis is that in the case of weak cytotoxic activation, dysplasia persists. We aimed to identify possible immunological markers of LGD presence and persistence. We prospectively enrolled 112 UC patients who underwent screening colonoscopy (T0) who had biopsies taken from their sigmoid colon. Ninety of them had at least a second colonoscopy (T1) with biopsies taken in the sigmoid colon and 8 patients had dysplasia in both examinations suggesting a persistence of LGD in their colon. Immunohistochemistry and real time polymerase chain reaction for CD4, CD69, CD107, and CD8β messenger RNA (mRNA) expression and flow cytometry for epithelial cells expressing CD80 or HLA avidin-biotin complex were performed. Non-parametric statistics, receiver operating characteristic curves analysis, and logistic multiple regression analysis were used. Thirteen patients had LGD diagnosed at T0. The mucosal mRNA expression of CD4, CD69, and CD8β was significantly lower than in patients without dysplasia (P = 0.033, P = 0.046 and P = 0.007, respectively). A second colonoscopy was performed in 90 patients after a median follow-up of 17 (12-25) months and 14 of the patients were diagnosed with LGD. In these patients, CD8β mRNA expression at T0 was significantly lower in patients without dysplasia (P = 0.004). A multivariate survival analysis in a model including CD8β mRNA levels and age >50 demonstrated that both items were independent predictors of dysplasia at follow-up (hazard ratio [HR] = 0.47 [95% confidence interval [CI]: 0.26-0.86], P = 0.014, and HR = 13.32 [95% CI: 1.72-102.92], P = 0.013). These data suggest a low cytotoxic T cell activation in the colonic mucosa of UC patients who do not manage to clear dysplasia. Thus, low level of CD8β mRNA expression in non-dysplastic colonic mucosa might be considered in future studies about the decision making of management of LGD in UC.
Identifiants
pubmed: 31343468
doi: 10.14309/ctg.0000000000000061
pmc: PMC6708661
doi:
Substances chimiques
Antigens, CD
0
Antigens, Differentiation, T-Lymphocyte
0
B7-1 Antigen
0
CD4 Antigens
0
CD69 antigen
0
CD8 Antigens
0
CD8beta antigen
0
Lectins, C-Type
0
Lysosomal-Associated Membrane Protein 1
0
Lysosomal-Associated Membrane Protein 2
0
RNA, Messenger
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00061Références
Gut. 2003 Aug;52(8):1127-32
pubmed: 12865270
Cell. 1992 Dec 24;71(7):1093-102
pubmed: 1335364
Am J Gastroenterol. 2015 Oct;110(10):1461-71; quiz 1472
pubmed: 26416190
J Clin Gastroenterol. 2003 May-Jun;36(5 Suppl):S70-4; discussion S94-6
pubmed: 12702969
Gastroenterology. 2003 Nov;125(5):1311-9
pubmed: 14598247
Nat Rev Immunol. 2006 Nov;6(11):836-48
pubmed: 17063185
Gut. 2001 Apr;48(4):526-35
pubmed: 11247898
Cancer Immunol Immunother. 2004 Jun;53(6):551-9
pubmed: 14727087
Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:1-5
pubmed: 12950413
Lancet. 1994 Jan 8;343(8889):71-4
pubmed: 7903776
Gut. 2010 May;59(5):666-89
pubmed: 20427401
BMC Gastroenterol. 2015 Dec 10;15:173
pubmed: 26652024
Science. 1993 Jan 15;259(5093):368-70
pubmed: 7678351
Best Pract Res Clin Gastroenterol. 2013 Apr;27(2):257-67
pubmed: 23809244
J Crohns Colitis. 2017 Jun 1;11(6):649-670
pubmed: 28158501
Immunol Today. 1997 Oct;18(10):493-7
pubmed: 9357142
Eur J Cancer. 2013 Jan;49(1):254-63
pubmed: 22704122
Oncotarget. 2015 Aug 21;6(24):20058-69
pubmed: 25595911
Gastroenterology. 2006 Apr;130(4):1030-8
pubmed: 16618396
Oncotarget. 2016 Mar 1;7(9):10322-31
pubmed: 26862732
Am J Gastroenterol. 2002 Apr;97(4):922-7
pubmed: 12008669
J Crohns Colitis. 2015 Jan;9(1):4-25
pubmed: 25304060
Ann Surg. 2006 Dec;244(6):986-92; discussion 992-3
pubmed: 17122624
Surgery. 2014 Aug;156(2):253-62
pubmed: 24947639
Digestion. 2010;82(3):179-86
pubmed: 20588031
Gut. 2000 Aug;47(2):251-5
pubmed: 10896917
Inflamm Bowel Dis. 2014 Dec;20(12):2340-52
pubmed: 25358065
Gut. 2008 Sep;57(9):1246-51
pubmed: 18337322
Aliment Pharmacol Ther. 2007 Mar 15;25(6):657-68
pubmed: 17311598
J Crohns Colitis. 2013 Nov;7(10):827-51
pubmed: 23870728
Gut. 2011 May;60(5):571-607
pubmed: 21464096
Gastroenterology. 1992 Nov;103(5):1444-51
pubmed: 1358741
Am J Gastroenterol. 2010 Jul;105(7):1610-9
pubmed: 20160714
Aliment Pharmacol Ther. 2013 Mar;37(5):546-54
pubmed: 23347191
Dis Colon Rectum. 2002 May;45(5):615-20
pubmed: 12004210
Dig Liver Dis. 2013 Mar;45(3):186-94
pubmed: 22974564